By adding a further piece of evidence in understanding the mechanisms of TF expression in monocytes, which are key cells in the atherothrombotic process, our results provide further support to the rationale for an effective ApoCIII-lowering therapy in cardiovascular diseases. The gene discussed is TF; the disease is cardiovascular disorder.